EDSA   $7.35  1.66% Market Closed After Close 7.126 -3.05%

Edesa Biotech, Inc.
Last Events:

2023-08-09 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Trend Power changed from slow to medium strength.

2023-08-06 Signal in Stochastic changed from bullish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: exit from the overbought zone.

2023-08-06 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-05 Signal in MACD changed from bullish reversal to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and it crossed the zero line from the bottom. These factors mean that there is probably a growing trend. Last signal: up-crossing the middle level.

2023-08-05 Signal in RSI changed from bearish to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-05 Signal in EMA100 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.


Current temperature: 5.35
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 11.00
Mean unverified/preliminary 11.00 / 11.00
Target Price Low / High 5.00 / 19.00
Median / STD DEV 9.00 / 7.21
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None ActivelyBuy None
rsi Sell ActivelyBuy None
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy None
ma50 None None None
ma100 None Buy None
Candlestick PatternMarch 3, 2026 Bearish Advance Block Formation - consists of three white bodies with consecutively higher closes in a uptrend. The last two days have long higher shadows. Considered to be a bullish reversal pattern.
ISIN CA27966L3065
ceo Dr. Pardeep Nijhawan FRCPC, M.D.
Website https://www.edesabiotech.com
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.